HLN

Haleon plc

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NYSE

County of HQ

GB

Next Earnings Date

Pending Announcement

Business Summary

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

 


Analyze HLN on TradingView

VALUATION

P/E

79.12

Market Cap ($M USD)

$40.23B

Forward P/E

15.99

PEG

0.04

PRICE TO SALES

3.62

PRICE TO BOOK

1.86

EV / EBITDA

17.89

5-Year Average P/E

Free Cash Flow Yield

3.12%

DCF Value

$20.03

Graham Number

$2.16

Price to FCF

32.03

EV to FCF

39.83

Earnings Yield

3.40%

FCF Yield

3.12%

DIVIDEND

Yield

2.11%

Annual Payout

$0.07

Payout Ratio

40.02%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.11

Next Year EPS Growth Estimate

$0.57

Next Year Revenue Growth Estimate

$13.60B

Return on Equity (ROE)

6.43%

FREE CASH FLOW

Operating Margin

18.85%

Debt-to-Equity

0.52

Piotroski F-Score

8

Altman Z-Score

3.34

Return on Invested Capital (ROIC)

5.61%

Current Ratio

0.92

Quick Ratio

0.71

Net Debt to EBITDA

3.50

Interest Coverage

12.83

Gross Profit margin

61.45%

FCF PER SHARE

$0.10

REVENUE PER SHARE

$0.91

Analyze HLN on TradingView

Gainseekers Quantitative Analysis

Summary

HLN Haleon plc’s valuation presents a compelling opportunity for value investors. Despite a snapshot price that traded significantly below its DCF value, the market seems to have overlooked its intrinsic worth. The Forward P/E of 15.99 suggests a more reasonable future valuation, contrasting sharply with its current high P/E, indicating potential growth. With an Altman Z-score of 3.31, the company is financially stable, and its earnings yield of 3.46% reflects a solid return on investment. This stock is undervalued relative to its fundamentals, offering a margin of safety for discerning investors.

AI Exposure / Tech Reliance

Operating within the healthcare sector, HLN is well-positioned to leverage AI and tech advancements. As a drug manufacturer, integrating AI can enhance R&D efficiency and streamline operations. This adaptability ensures resilience in a rapidly evolving technological landscape.

The Bull Case

For GARP investors, HLN offers a robust bull case. The company's ROIC of 5.61% and a Piotroski F-Score of 8 highlight strong operational efficiency and financial health. Its operating margin of 18.85% and gross profit margin of 61.45% indicate significant pricing power. Despite a modest FCF yield of 3.17%, the company's ability to generate cash flow supports its growth narrative, making it an attractive buy.

The Bear Case

However, the bear case cannot be ignored. The Price/Book ratio of 1.83 and Price/Sales of 3.57 suggest the stock is not cheap by traditional metrics. Its current ratio of 0.92 and quick ratio of 0.71 raise concerns about short-term liquidity. Additionally, a high EV to FCF of 39.38 indicates potential overvaluation relative to cash flow. These factors could pose risks if market conditions shift unfavorably.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$10.20

Institutional Ownership %

1-Year Beta

0.25

Insider Buying % (6 Mo)

Distance to 52-Week High

26.05%

Distance to 52-Week Low

3.86%

EARNINGS SURPRISE %

3.38%

50-DAY SMA

$9.52

200-DAY SMA

$9.77

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.